BioAge Labs (BIOA) Accounts Payables (2023 - 2026)

BioAge Labs has disclosed Accounts Payables across 4 years of filings, most recently posting $5.7 million for Q2 2026.

• In Q2 2026, Accounts Payables rose 325.36% year-over-year to $5.7 million; the TTM figure through Jun 2026 stood at $5.7 million (up 325.36% YoY), while the FY2025 annual figure was $2.7 million, up 33.97% from the prior year.
• Accounts Payables came in at $5.7 million for Q2 2026 at BioAge Labs, up from $3.1 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $5.7 million in Q2 2026 to a low of $1.3 million in Q2 2025.
• Average Accounts Payables over 4 years is $3.1 million, with a median of $2.7 million recorded in 2025.
• The largest YoY upside for Accounts Payables was 325.36% in 2026 against a maximum downside of 23.14% in 2026.
• Over 4 years, Accounts Payables stood at $1.9 million in 2023, then advanced by 6.97% to $2.0 million in 2024, then soared by 33.97% to $2.7 million in 2025, then soared by 111.41% to $5.7 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $5.7 million in Q2 2026, $3.1 million in Q1 2026, and $2.7 million in Q4 2025.